Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Enrolling by invitation

Conditions studied: Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity

In brief

This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.

Key facts

Study ID

NCT06167642

Run by

Johns Hopkins University

People needed

75

Starts

2023-05-22

Expected to finish

2027-03-01

Last updated by the study team

2026-06-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Between 18 - 70 years of age
• Have RMS as confirmed by the treating neurologist based on the 2017 revised McDonald criteria
• AND Either
• be due to commence ofatumumab within 60 days of baseline OCT/VA/phlebotomy or
• be existing patients attending the center and already receiving ofatumumab, be eligible for inclusion, and already undergoing all of the proposed study procedures.
• Willing to sign informed consent
• Willing to undergo phlebotomy

You may not qualify if…

• Uncontrolled Diabetes
• Uncontrolled Hypertension
• Glaucoma
• Refractive errors of +/- 6 diopters
• Other neurologic or ophthalmologic disorders

Where it is running

• Johns Hopkins — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.